Coordinated by the Sclavo Vaccines Association, the EVH project involves 11 beneficiaries and 13 affiliated entities from seven European countries, all focusing on enhancing pandemic preparedness.

This collaboration aims to facilitate efficient innovation transfer and strengthen healthcare systems and pandemic preparedness across Europe.

The project seeks to develop pandemic-prototype vaccines and scalable technologies through collaboration among major EU vaccine research and development institutions.

Additionally, it aims to establish a public-private partnership to ensure independent vaccine development and manufacturing capabilities in Europe for future pandemics.

The initiative is designed to create a proactive research and development system and knowledge hub, refining processes for vaccine development against critical pathogens identified by the WHO.

An official kick-off meeting for the EVH was held on May 22-23, 2025, at the University of Siena, with over 160 participants from various institutions, including the European Commission and national health authorities.

The EVH project is co-funded by the EU's EU4Health program, boasting a total budget of approximately 170 million euros, which includes 102 million euros from the EU.

The European Health and Digital Executive Agency (HaDEA) has initiated the European Vaccines Hub for Pandemic Readiness (EVH) to bolster public health and vaccine development across Europe.

The EVH is organized around four main pillars: Discovery led by Fondazione Biotecnopolo di Siena in Italy, Preclinical studies by Institut Pasteur in France, Clinical studies by Vaccinopolis in Belgium, and Manufacturing by the German Center for Infection Research (DZIF) in Germany.

DZIF will utilize its expertise in translational vaccine research and regulatory support to improve the vaccine development process within the EVH framework.